Terminated PHASE2 INTERVENTIONAL 3-arm NCT04378010

A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH

A Phase 2b Randomized, Double-Blind, Placebo-controlled, Multicenter Study Evaluating Safety and Efficacy of EDP-305 in Subjects With Liver Biopsy Proven Non-alcoholic Steatohepatitis (NASH) (ARGON-2)

Sponsor: Enanta Pharmaceuticals, Inc

Conditions Non-Alcoholic Steatohepatitis

Interventions EDP-305 1.5 mg EDP-305 2 mg Placebo

Updated 10 times since 2020 Last updated: Apr 25, 2023 Started: Jan 27, 2020 Primary completion: Oct 4, 2021 Completion: Nov 30, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Enanta Pharmaceuticals, Inc. made the strategic decision to discontinue the ARGON-2 study to prioritize combination treatment approaches. This decision was not based on safety concerns.

Other terminated trials from Enanta Pharmaceuticals, Inc

More terminations from Enanta Pharmaceuticals, Inc

Listed as NCT04378010, this PHASE2 trial focuses on Non-Alcoholic Steatohepatitis and remains terminated or withdrawn. Sponsored by Enanta Pharmaceuticals, Inc, it has been updated 10 times since 2020, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

10 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE2
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jun 2023 — Jul 2024 [monthly]

Terminated PHASE2

Status: Recruiting → Terminated
Nov 2022 — Jun 2023 [monthly]

Recruiting PHASE2

▶ Show 5 earlier versions

Sep 2021 — Nov 2022 [monthly]

Recruiting PHASE2
Jan 2021 — Sep 2021 [monthly]

Recruiting PHASE2
Sep 2020 — Jan 2021 [monthly]

Recruiting PHASE2
Aug 2020 — Sep 2020 [monthly]

Recruiting PHASE2

Status: Active Not Recruiting → Recruiting
Jun 2020 — Aug 2020 [monthly]

Active Not Recruiting PHASE2

First recorded

Jan 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Enanta Pharmaceuticals, Inc

Data source: Enanta Pharmaceuticals, Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Arlington, United States , Atlanta, United States , Austin, United States , Bakersfield, United States , Baltimore, United States , Buenos Aires, Argentina , Calgary, Canada , Catonsville, United States , Chandler, United States , Chicago, United States and 63 more locations